Please assess the completion status of the following clinical trial:

Trial Title: Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female MG patients age greater than 18 and less than 65 years~* Onset of generalized MG within the last 5 years~* Positive serum anti-acetylcholine receptor binding antibodies (muscle acetylcholine receptors, AchRAb =/\> 1.00 nmol/L. AchRAb levels of 0.50-0.99 nmol/L will be acceptable if there is another confirmatory test for MG, including single-fiber electromyography (EMG), repetitive nerve stimulation, or unequivocal edrophonium testing.)~* MGFA class II-IV at entry, using the MG Foundation of America (MGFA) classification, while receiving optimal anti-cholinesterase treatment with or without oral prednisone~Exclusion Criteria:~* Ocular MG without generalized weakness (MGFA Class I) or minimal weakness that would not require the use of corticosteroids~* Myasthenic weakness requiring intubation (MGFA Class IV) in the prior month~* Immunosuppressive therapy other than corticosteroids in the preceding year~* Medically unfit for thymectomy~* Chest CT evidence of thymoma.~* Pregnancy or lactation; contraindications to the use of corticosteroids, unless postmenopausal or surgically sterile. Women considering becoming pregnant during the period of the study are to be excluded.~* A serious concurrent medical, neurological or psychiatric condition that would interfere with thymectomy or subsequent clinical assessments~* Current alternate day dose of prednisone \> than 1.5 mg/kg or 100 mg or the equivalent daily doses (\> 0.75 mg/kg or 50 mg).~* Participation in another experimental clinical trial~* History of alcohol or drug abuse within the 2 years prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Thymectomy plus prednisone (Type: ACTIVE_COMPARATOR): Procedure: Extended Transsternal Thymectomy plus prednisone treatment
- Prednisone alone (Type: PLACEBO_COMPARATOR): Drug: prednisone alone protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).